Patents by Inventor Andrew J. Kassick

Andrew J. Kassick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20240132509
    Abstract: Disclosed are quinoline and quinazoline compounds which modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include quinoline or quinazoline derivatives substituted at the 4-position via N(H), C(O) or O moieties.
    Type: Application
    Filed: November 13, 2023
    Publication date: April 25, 2024
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Michael A. Arnold, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Aleksey I. Gerasyuto, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Matthew G. Woll, Wuming Yan, Nanjing Zhang
  • Heterocyclic and heteroaryl compounds for treating Huntington's disease
    Patent number: 11858941
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: January 2, 2024
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Michael A. Arnold, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Aleksey I. Gerasyuto, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Matthew G. Woll, Wuming Yan, Nanjing Zhang
  • GLUCOSE-RESPONSIVE INSULIN CONJUGATES
    Publication number: 20220273770
    Abstract: Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 1, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Andrew J. Kassick, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
  • HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20210284660
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 16, 2021
    Inventors: Nanjing Zhang, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Guangming Chen, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Nadiya Sydorenko, Anthony Turpoff, Matthew G. Woll, Wuming Yan
  • HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20210238186
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: June 25, 2019
    Publication date: August 5, 2021
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Michael A. Arnold, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Aleksey I. Gerasyuto, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Matthew G. Woll, Wuming Yan, Nanjing Zhang
  • Cyclic benzimidazole derivatives useful as anti-diabetic agents
    Patent number: 8895596
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: November 25, 2014
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Jinlong Jiang, Andrew J. Kassick, Ahmet Kekec, Iyassu K. Sebhat
  • NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS
    Publication number: 20120309736
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: February 21, 2011
    Publication date: December 6, 2012
    Inventors: Jinlong Jiang, Andrew J. Kassick, Ahmet Kekec, Iyassu K. Sebhat
  • Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
    Patent number: 8124633
    Abstract: The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: February 28, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert J. DeVita, Sander G. Mills, Jinlong Jiang, Andrew J. Kassick, Jianming Bao
  • HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS
    Publication number: 20100105747
    Abstract: The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.
    Type: Application
    Filed: April 7, 2008
    Publication date: April 29, 2010
    Inventors: Robert J. DeVita, Sander G. Mills, Jinlong Jiang, Andrew J. Kassick, Jianming Bao